Para Advisors LLC is an employee owned investment manager that primarily provides its services to pooled investment vehicles. The firm also provides its services to charitable organizations and investment companies. The SEC 13F filings submitted by Para Advisors LLC for the period ended September 30, 2014, indicated that the firm’s primary holdings are Allergan, Inc. (NYSE:AGN), Time Warner Cable Inc (NYSE:TWC), and TRW Automotive Holdings Corp. (NYSE:TRW).
The biggest investment of Para Advisors LLC for the period was Allergan, Inc. (NYSE:AGN), which accounted for investment worth $10.69 million. Allergan, Inc. (NYSE:AGN) is a multi-specialty worldwide health care company, focusing on the discovery, development, and commercialization of innovative pharmaceuticals biologics, over-the-counter products, and medical devices. Pershing Square was the holding with the biggest stake at the company with 28.88 million shares. Paulson & Co was second with 5.38 million shares. (You can see complete list of hedge funds which hold positions on Allergan, Inc. (NYSE:AGN) at the end of third quarter.)
The second on the list was Time Warner Cable Inc (NYSE:TWC), accounting for a total value of $7.18 million. Time Warner Cable Inc (NYSE:TWC) is a cable telecommunications company, currently operating in 29 states of the U.S. The company provides video, high speed data and voice services, among other services such as networking and transportation. Time Warner Cable Inc (NYSE:TWC) was named “The Best Place to Work” on 2015 Corporate Quality Index (CEI), based on its policies and practices with relation to LGBT.
TRW Automotive Holdings Corp. (NYSE:TRW) emerged as the third biggest investment of Para Advisors LLC, with investment valued at $7.09 million. TRW Automotive Holdings Corp. (NYSE:TRW) is a global provider of automotive systems, modules, and components to automotive original equipment. Some of the categories of products supplied by the company are passive and active safety products. Morningstar recently gave the stock a “SUS” credit rating and a two star stock rating. FBR Capital Markets analysts have also recently raised the price target of the company to $105.6 from $84. Zacks have however downgraded the stock from “outperform” to “neutral” with a price target of $106.
This article has been written by Victor Ochieng.
Related articles:
Actavis PLC (ACT), AbbVie Inc (ABBV), Allergan, Inc. (AGN): Top 3 Holdings of Oz Management
The Only 9 Teams with a Chance to Win the Super Bowl
The 15 Most Common Phobias in America that Induce Fits of Panic
